Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas
- PMID: 2910510
- DOI: 10.1007/BF00273532
Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas
Abstract
In a phase II study we evaluated the effect and toxicity of a new alkylating agent, PTT-119, in 26 patients with non-Hodgkin's lymphomas (NHL) resistant to or relapsed after other chemotherapy. PTT was scheduled by escalating the dose from 2.0 to 3.3 mg/kg every 3 weeks. Among 21 evaluable patients with NHL, 12 (57%) showed a good response (CR + PR) to PTT-119. Tolerance was acceptably good; no major side effects related to liver, cardiac, or renal toxicity were recorded. The most commonly recorded side effects were nausea and vomiting, alopecia, and phlebitis; diarrhea and drug-related fever were rarely seen. This report indicates a potential usefulness for PTT-119, a non-cross-resistant alkylating agent, in the treatment of NHL.
Similar articles
-
Phase II cooperative study with a new alkylating drug, PTT-119, in the treatment of non-Hodgkin's lymphomas.Blut. 1990 Mar;60(3):172-6. doi: 10.1007/BF01720271. Blut. 1990. PMID: 2317568
-
Drug essentials. An alkylating agent for CLL and NHL.Oncology (Williston Park). 2009 Apr;23(4 Suppl Nurse Ed):55-6. Oncology (Williston Park). 2009. PMID: 19856600 No abstract available.
-
Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma.Ann Oncol. 2002 Aug;13(8):1285-9. doi: 10.1093/annonc/mdf189. Ann Oncol. 2002. PMID: 12181253 Clinical Trial.
-
Bendamustine in chronic lymphocytic leukemia and non-Hodgkin's lymphoma.Expert Rev Anticancer Ther. 2010 Sep;10(9):1353-65. doi: 10.1586/era.10.116. Expert Rev Anticancer Ther. 2010. PMID: 20836669 Review.
-
Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia.Am J Health Syst Pharm. 2010 May 1;67(9):713-23. doi: 10.2146/ajhp090328. Am J Health Syst Pharm. 2010. PMID: 20410545 Review.
Cited by
-
Evidence for increased intracellular transport of m-sarcolysine (alkylating moiety) when combined with two amino acid analogs (PTT-119).Blut. 1990 Nov;61(5):311-3. doi: 10.1007/BF01732884. Blut. 1990. PMID: 2271778
-
Phase II cooperative study with a new alkylating drug, PTT-119, in the treatment of non-Hodgkin's lymphomas.Blut. 1990 Mar;60(3):172-6. doi: 10.1007/BF01720271. Blut. 1990. PMID: 2317568
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials